Annual Net Income
$3.62 B
+$297.60 M+8.96%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual net profit is currently $3.62 billion, with the most recent change of +$297.60 million (+8.96%) on 31 December 2023. During the last 3 years, it has risen by +$907.90 million (+33.48%). VRTX annual net income is now at all-time high.VRTX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$1.05 B
+$4.64 B+129.09%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly net profit is currently $1.05 billion, with the most recent change of +$4.64 billion (+129.09%) on 30 September 2024. Over the past year, it has increased by +$10.10 million (+0.98%). VRTX quarterly net income is now -32.58% below its all-time high of $1.55 billion, reached on 31 December 2018.VRTX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$479.80 M
+$10.10 M+2.06%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM net profit is currently -$479.80 million, with the most recent change of +$10.10 million (+2.06%) on 30 September 2024. Over the past year, it has dropped by -$3.95 billion (-113.83%). VRTX TTM net income is now -111.94% below its all-time high of $4.02 billion, reached on 31 March 2024.VRTX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.0% | +1.0% | -113.8% |
| 3 y3 years | +33.5% | +22.7% | -122.0% |
| 5 y5 years | +72.6% | +1717.5% | -122.4% |
VRTX Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.5% | -4.9% | +129.1% | -111.9% | +2.1% |
| 5 y | 5 years | at high | +207.6% | -4.9% | +129.1% | -111.9% | +2.1% |
| alltime | all time | at high | +579.6% | -32.6% | +129.1% | -111.9% | +37.3% |
Vertex Pharmaceuticals Incorporated Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.05 B(-129.1%) | -$479.80 M(-2.1%) |
| June 2024 | - | -$3.59 B(-426.8%) | -$489.90 M(-112.2%) |
| Mar 2024 | - | $1.10 B(+13.5%) | $4.02 B(+11.0%) |
| Dec 2023 | $3.62 B(+9.0%) | $968.80 M(-6.4%) | $3.62 B(+4.3%) |
| Sept 2023 | - | $1.04 B(+13.1%) | $3.47 B(+3.1%) |
| June 2023 | - | $915.70 M(+30.9%) | $3.36 B(+3.2%) |
| Mar 2023 | - | $699.80 M(-14.5%) | $3.26 B(-1.9%) |
| Dec 2022 | $3.32 B(+41.8%) | $818.90 M(-12.0%) | $3.32 B(+1.5%) |
| Sept 2022 | - | $930.50 M(+14.8%) | $3.27 B(+2.5%) |
| June 2022 | - | $810.50 M(+6.4%) | $3.19 B(+30.3%) |
| Mar 2022 | - | $762.10 M(-1.0%) | $2.45 B(+4.7%) |
| Dec 2021 | $2.34 B(-13.6%) | $770.10 M(-9.6%) | $2.34 B(+7.6%) |
| Sept 2021 | - | $851.90 M(+1171.5%) | $2.18 B(+9.3%) |
| June 2021 | - | $67.00 M(-89.7%) | $1.99 B(-27.9%) |
| Mar 2021 | - | $653.10 M(+8.1%) | $2.76 B(+1.9%) |
| Dec 2020 | $2.71 B(+130.4%) | $604.24 M(-9.5%) | $2.71 B(+0.8%) |
| Sept 2020 | - | $667.43 M(-20.3%) | $2.69 B(+29.3%) |
| June 2020 | - | $837.27 M(+38.9%) | $2.08 B(+37.7%) |
| Mar 2020 | - | $602.75 M(+3.3%) | $1.51 B(+28.4%) |
| Dec 2019 | $1.18 B(-43.9%) | $583.22 M(+914.0%) | $1.18 B(-45.1%) |
| Sept 2019 | - | $57.52 M(-78.5%) | $2.14 B(-3.2%) |
| June 2019 | - | $267.43 M(-0.4%) | $2.22 B(+2.8%) |
| Mar 2019 | - | $268.63 M(-82.7%) | $2.16 B(+2.8%) |
| Dec 2018 | $2.10 B(+695.8%) | $1.55 B(+1104.3%) | $2.10 B(+224.1%) |
| Sept 2018 | - | $128.75 M(-37.9%) | $647.05 M(+55.8%) |
| June 2018 | - | $207.36 M(-1.4%) | $415.36 M(+83.8%) |
| Mar 2018 | - | $210.26 M(+108.8%) | $225.99 M(-14.2%) |
| Dec 2017 | $263.48 M(-335.1%) | $100.68 M(-197.8%) | $263.48 M(+34.6%) |
| Sept 2017 | - | -$102.95 M(-672.1%) | $195.75 M(-24.7%) |
| June 2017 | - | $18.00 M(-92.7%) | $259.86 M(+46.5%) |
| Mar 2017 | - | $247.76 M(+652.0%) | $177.34 M(-258.3%) |
| Dec 2016 | -$112.05 M(-79.9%) | $32.95 M(-184.8%) | -$112.05 M(-48.8%) |
| Sept 2016 | - | -$38.84 M(-39.8%) | -$218.73 M(-20.5%) |
| June 2016 | - | -$64.53 M(+55.0%) | -$275.04 M(-31.1%) |
| Mar 2016 | - | -$41.63 M(-43.5%) | -$399.36 M(-28.2%) |
| Dec 2015 | -$556.33 M(-24.7%) | -$73.73 M(-22.5%) | -$556.33 M(-15.6%) |
| Sept 2015 | - | -$95.15 M(-49.6%) | -$659.26 M(-10.2%) |
| June 2015 | - | -$188.85 M(-4.9%) | -$734.17 M(+4.2%) |
| Mar 2015 | - | -$198.61 M(+12.4%) | -$704.70 M(-4.6%) |
| Dec 2014 | -$738.55 M(+66.0%) | -$176.66 M(+3.9%) | -$738.55 M(+42.7%) |
| Sept 2014 | - | -$170.06 M(+6.7%) | -$517.61 M(+9.7%) |
| June 2014 | - | -$159.38 M(-31.4%) | -$471.69 M(+27.7%) |
| Mar 2014 | - | -$232.46 M(-624.9%) | -$369.47 M(-17.0%) |
| Dec 2013 | -$445.03 M(+315.8%) | $44.28 M(-135.7%) | -$445.03 M(-21.3%) |
| Sept 2013 | - | -$124.13 M(+117.1%) | -$565.46 M(+13.3%) |
| June 2013 | - | -$57.16 M(-81.4%) | -$498.87 M(-1.5%) |
| Mar 2013 | - | -$308.02 M(+304.5%) | -$506.64 M(+373.4%) |
| Dec 2012 | -$107.03 M(-461.9%) | -$76.15 M(+32.3%) | -$107.03 M(-183.8%) |
| Sept 2012 | - | -$57.54 M(-11.4%) | $127.75 M(-68.6%) |
| June 2012 | - | -$64.93 M(-170.9%) | $406.40 M(+36.7%) |
| Mar 2012 | - | $91.59 M(-42.3%) | $297.26 M(+905.1%) |
| Dec 2011 | $29.57 M(-103.9%) | $158.63 M(-28.3%) | $29.57 M(-109.6%) |
| Sept 2011 | - | $221.11 M(-227.0%) | -$309.45 M(-58.2%) |
| June 2011 | - | -$174.07 M(-1.2%) | -$739.51 M(-3.4%) |
| Mar 2011 | - | -$176.10 M(-2.4%) | -$765.45 M(+1.4%) |
| Dec 2010 | -$754.63 M(+17.5%) | -$180.39 M(-13.7%) | -$754.63 M(+3.0%) |
| Sept 2010 | - | -$208.96 M(+4.5%) | -$732.88 M(+8.8%) |
| June 2010 | - | -$200.01 M(+21.0%) | -$673.49 M(+4.5%) |
| Mar 2010 | - | -$165.27 M(+4.2%) | -$644.78 M(+0.4%) |
| Dec 2009 | -$642.18 M(+39.6%) | -$158.64 M(+6.1%) | -$642.18 M(+2.6%) |
| Sept 2009 | - | -$149.56 M(-12.7%) | -$625.87 M(+3.2%) |
| June 2009 | - | -$171.30 M(+5.3%) | -$606.35 M(+15.2%) |
| Mar 2009 | - | -$162.67 M(+14.3%) | -$526.37 M(+14.5%) |
| Dec 2008 | -$459.85 M(+17.5%) | -$142.33 M(+9.4%) | -$459.85 M(+14.0%) |
| Sept 2008 | - | -$130.04 M(+42.4%) | -$403.27 M(+6.1%) |
| June 2008 | - | -$91.32 M(-5.0%) | -$380.26 M(-6.5%) |
| Mar 2008 | - | -$96.15 M(+12.1%) | -$406.70 M(+3.9%) |
| Dec 2007 | -$391.28 M | -$85.75 M(-19.9%) | -$391.28 M(+17.5%) |
| Sept 2007 | - | -$107.03 M(-9.1%) | -$332.87 M(+19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$117.77 M(+45.9%) | -$277.64 M(+16.9%) |
| Mar 2007 | - | -$80.73 M(+195.2%) | -$237.53 M(+14.8%) |
| Dec 2006 | -$206.89 M(+1.7%) | -$27.34 M(-47.2%) | -$206.89 M(-5.0%) |
| Sept 2006 | - | -$51.80 M(-33.3%) | -$217.68 M(-11.3%) |
| June 2006 | - | -$77.66 M(+55.0%) | -$245.45 M(+17.6%) |
| Mar 2006 | - | -$50.09 M(+31.4%) | -$208.78 M(+2.6%) |
| Dec 2005 | -$203.42 M(+22.4%) | -$38.13 M(-52.1%) | -$203.42 M(-2.2%) |
| Sept 2005 | - | -$79.58 M(+94.1%) | -$208.06 M(+24.4%) |
| June 2005 | - | -$40.99 M(-8.3%) | -$167.25 M(-1.9%) |
| Mar 2005 | - | -$44.72 M(+4.6%) | -$170.53 M(+2.6%) |
| Dec 2004 | -$166.25 M(-15.5%) | -$42.77 M(+10.3%) | -$166.25 M(+1.1%) |
| Sept 2004 | - | -$38.77 M(-12.4%) | -$164.51 M(-22.5%) |
| June 2004 | - | -$44.27 M(+9.5%) | -$212.16 M(-0.7%) |
| Mar 2004 | - | -$40.44 M(-1.4%) | -$213.69 M(+40.0%) |
| Dec 2003 | -$196.77 M(+81.2%) | -$41.03 M(-52.5%) | -$152.64 M(+6.2%) |
| Sept 2003 | - | -$86.42 M(+88.7%) | -$143.69 M(+58.4%) |
| June 2003 | - | -$45.80 M(-322.2%) | -$90.72 M(+37.6%) |
| Mar 2003 | - | $20.61 M(-164.2%) | -$65.94 M(-39.3%) |
| Dec 2002 | -$108.62 M(+64.0%) | -$32.08 M(-4.1%) | -$108.62 M(+36.1%) |
| Sept 2002 | - | -$33.45 M(+59.2%) | -$79.80 M(+38.0%) |
| June 2002 | - | -$21.02 M(-4.7%) | -$57.83 M(+18.2%) |
| Mar 2002 | - | -$22.07 M(+576.9%) | -$48.91 M(+36.9%) |
| Dec 2001 | -$66.23 M(+90.7%) | -$3.26 M(-71.6%) | -$35.72 M(-7.9%) |
| Sept 2001 | - | -$11.48 M(-5.2%) | -$38.79 M(-25.6%) |
| June 2001 | - | -$12.11 M(+36.5%) | -$52.17 M(+90.1%) |
| Mar 2001 | - | -$8.87 M(+40.0%) | -$27.45 M(-26.4%) |
| Dec 2000 | -$34.74 M(-15.3%) | -$6.34 M(-74.5%) | -$37.29 M(+27.5%) |
| Sept 2000 | - | -$24.86 M(-297.1%) | -$29.26 M(+56.5%) |
| June 2000 | - | $12.61 M(-167.4%) | -$18.70 M(-55.6%) |
| Mar 2000 | - | -$18.71 M(-1200.6%) | -$42.15 M(+2.7%) |
| Dec 1999 | -$41.00 M(+23.9%) | $1.70 M(-111.9%) | -$41.04 M(-25.8%) |
| Sept 1999 | - | -$14.30 M(+31.9%) | -$55.34 M(+27.7%) |
| June 1999 | - | -$10.84 M(-38.4%) | -$43.34 M(+2.5%) |
| Mar 1999 | - | -$17.60 M(+39.7%) | -$42.30 M(+27.8%) |
| Dec 1998 | -$33.10 M(+67.2%) | -$12.60 M(+447.8%) | -$33.10 M(+21.2%) |
| Sept 1998 | - | -$2.30 M(-76.5%) | -$27.30 M(-11.7%) |
| June 1998 | - | -$9.80 M(+16.7%) | -$30.90 M(+37.3%) |
| Mar 1998 | - | -$8.40 M(+23.5%) | -$22.50 M(+13.1%) |
| Dec 1997 | -$19.80 M(-50.5%) | -$6.80 M(+15.3%) | -$19.90 M(+17.1%) |
| Sept 1997 | - | -$5.90 M(+321.4%) | -$17.00 M(-2.3%) |
| June 1997 | - | -$1.40 M(-75.9%) | -$17.40 M(-54.6%) |
| Mar 1997 | - | -$5.80 M(+48.7%) | -$38.30 M(-4.3%) |
| Dec 1996 | -$40.00 M(+86.0%) | -$3.90 M(-38.1%) | -$40.00 M(+8.4%) |
| Sept 1996 | - | -$6.30 M(-71.7%) | -$36.90 M(-1.6%) |
| June 1996 | - | -$22.30 M(+197.3%) | -$37.50 M(+55.0%) |
| Mar 1996 | - | -$7.50 M(+837.5%) | -$24.20 M(+13.1%) |
| Dec 1995 | -$21.50 M(+22.2%) | -$800.00 K(-88.4%) | -$21.40 M(-16.1%) |
| Sept 1995 | - | -$6.90 M(-23.3%) | -$25.50 M(+13.3%) |
| June 1995 | - | -$9.00 M(+91.5%) | -$22.50 M(+18.4%) |
| Mar 1995 | - | -$4.70 M(-4.1%) | -$19.00 M(+8.6%) |
| Dec 1994 | -$17.60 M(-980.0%) | -$4.90 M(+25.6%) | -$17.50 M(+348.7%) |
| Sept 1994 | - | -$3.90 M(-29.1%) | -$3.90 M(+44.4%) |
| June 1994 | - | -$5.50 M(+71.9%) | -$2.70 M(-235.0%) |
| Mar 1994 | - | -$3.20 M(-136.8%) | $2.00 M(+5.3%) |
| Dec 1993 | $2.00 M(-123.5%) | $8.70 M(-422.2%) | $1.90 M(-120.0%) |
| Sept 1993 | - | -$2.70 M(+237.5%) | -$9.50 M(+5.6%) |
| June 1993 | - | -$800.00 K(-75.8%) | -$9.00 M(-10.9%) |
| Mar 1993 | - | -$3.30 M(+22.2%) | -$10.10 M(+20.2%) |
| Dec 1992 | -$8.50 M(+66.7%) | -$2.70 M(+22.7%) | -$8.40 M(+20.0%) |
| Sept 1992 | - | -$2.20 M(+15.8%) | -$7.00 M(+16.7%) |
| June 1992 | - | -$1.90 M(+18.8%) | -$6.00 M(+9.1%) |
| Mar 1992 | - | -$1.60 M(+23.1%) | -$5.50 M(+7.8%) |
| Dec 1991 | -$5.10 M(+18.6%) | -$1.30 M(+8.3%) | -$5.10 M(+4.1%) |
| Sept 1991 | - | -$1.20 M(-14.3%) | -$4.90 M(+2.1%) |
| June 1991 | - | -$1.40 M(+16.7%) | -$4.80 M(+6.7%) |
| Mar 1991 | - | -$1.20 M(+9.1%) | -$4.50 M(+4.7%) |
| Dec 1990 | -$4.30 M | -$1.10 M(0.0%) | -$4.30 M(+34.4%) |
| Sept 1990 | - | -$1.10 M(0.0%) | -$3.20 M(+52.4%) |
| June 1990 | - | -$1.10 M(+10.0%) | -$2.10 M(+110.0%) |
| Mar 1990 | - | -$1.00 M | -$1.00 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual net profit?
- What is the all time high annual net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual net income year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly net profit?
- What is the all time high quarterly net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly net income year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM net profit?
- What is the all time high TTM net income for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM net income year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual net profit?
The current annual net income of VRTX is $3.62 B
What is the all time high annual net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual net profit is $3.62 B
What is Vertex Pharmaceuticals Incorporated annual net income year-on-year change?
Over the past year, VRTX annual net profit has changed by +$297.60 M (+8.96%)
What is Vertex Pharmaceuticals Incorporated quarterly net profit?
The current quarterly net income of VRTX is $1.05 B
What is the all time high quarterly net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly net profit is $1.55 B
What is Vertex Pharmaceuticals Incorporated quarterly net income year-on-year change?
Over the past year, VRTX quarterly net profit has changed by +$10.10 M (+0.98%)
What is Vertex Pharmaceuticals Incorporated TTM net profit?
The current TTM net income of VRTX is -$479.80 M
What is the all time high TTM net income for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM net profit is $4.02 B
What is Vertex Pharmaceuticals Incorporated TTM net income year-on-year change?
Over the past year, VRTX TTM net profit has changed by -$3.95 B (-113.83%)